Home › Compound Library › Omeprazole (Prilosec)

Omeprazole (Prilosec)

Proton Pump Inhibitororal · inferred

Proton pump inhibitor that irreversibly binds H+/K+ ATPase. Despite its short plasma half-life (<1 hr), acid suppression lasts 24+ hours due to covalent enzyme binding.

Projected serum levels — 20 mg, once daily

Omeprazole (Prilosec)
Omeprazole (Prilosec) modeled serum levels, 20 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 1.3 2.5 3.8 5 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 20 mg once daily (oral).

Modeled steady state after ~1 days: peak ≈ 3.1 mg, trough ≈ 0.000 mg body load. Population-based estimate over 15 days for a 20 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Proton Pump Inhibitor
Route modeled
Oral
Model confidence
inferred
Half-life
1 h
Common dose
20 mg
Suggested maximum
40 mg/day
Reference dose range
10–40 mg (single dose)
Suggested cadence
once daily
Validated against
20 mg oral — Cmax 0.76 mg/L at 1.5 h

Documented interactions

  • danger
    CBD (Cannabidiol) + Omeprazole (Prilosec) CYP inhibition

    CBD (Cannabidiol) reversible_inhibitor of CYP2C19 predicted to change Omeprazole (Prilosec) AUC by ~2.27x

  • danger
    Efavirenz (Sustiva) + Omeprazole (Prilosec) CYP induction

    Efavirenz (Sustiva) inducer of CYP3A4 predicted to change Omeprazole (Prilosec) AUC by ~0.42x

  • danger
    Esomeprazole (Nexium) + Omeprazole (Prilosec) CYP inhibition

    Omeprazole (Prilosec) reversible_inhibitor of CYP2C19 predicted to change Esomeprazole (Nexium) AUC by ~2.07x

  • danger
    Ethinyl Estradiol + Omeprazole (Prilosec) CYP inhibition

    Ethinyl Estradiol reversible_inhibitor of CYP2C19 predicted to change Omeprazole (Prilosec) AUC by ~2.27x

  • danger
    Fluconazole + Omeprazole (Prilosec) CYP inhibition

    Fluconazole reversible_inhibitor of CYP2C19 predicted to change Omeprazole (Prilosec) AUC by ~2.27x

  • danger
    Fluoxetine (Prozac) + Omeprazole (Prilosec) CYP inhibition

    Fluoxetine (Prozac) reversible_inhibitor of CYP2C19 predicted to change Omeprazole (Prilosec) AUC by ~2.27x

Serum checks 101 modeled interaction pairings for omeprazole (prilosec) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Proton pump inhibitors: review of emerging concerns Heidelbaugh JJ · Annals of Family Medicine, 2013 DOI

    Review of PPI safety concerns including associations with bone fractures, C. difficile infection, pneumonia, and potential magnesium/B12 deficiency with long-term use.

  2. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs Laheij RJ et al. · JAMA, 2004 DOI

    Large population-based study found PPI use was associated with a 1.89-fold increased risk of community-acquired pneumonia, likely due to reduced gastric acid barrier.

  3. Comparative effectiveness of proton pump inhibitors for the treatment of GERD Fock KM et al. · Alimentary Pharmacology & Therapeutics, 2008 DOI

    Review comparing PPIs found omeprazole effective for healing erosive esophagitis in 80-90% of patients within 8 weeks, with all PPIs showing similar efficacy at equivalent doses.

3 published studies referenced in the app, each with a plain-language summary.